Oxford BioMedica Total Voting Rights

RNS Number : 1829J

Oxford Biomedica PLC

01 April 2015

 

Oxford BioMedica

Total Voting Rights

Oxford, UK - 1 April 2015: Oxford BioMedica plc ("Oxford BioMedica" or "the Company") (LSE: OXB), announces that in accordance with the FCA's Disclosure and Transparency Rule 5.6.1, the Company's issued share capital as at the close of business on 31 March 2015 consists of 2,567,670,557 ordinary shares of 1 pence each ("Ordinary Shares"). There are no Ordinary Shares held in treasury.

Accordingly, the total number of voting rights in Oxford BioMedica plc at the date of this notice is 2,567,670,557.

The above figure (2,567,670,557) may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Oxford BioMedica plc under the FCA's Disclosure and Transparency Rules.

- Ends -

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer Tim Watts, Chief Financial Officer	Tel: [phone]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal/Chris Welsh/Laura Thornton	Tel: [phone]

Notes for editors

About Oxford BioMedica^®

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world's largest pharmaceutical companies. Leveraging its proprietary LentiVector^® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of seven gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp.  In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions and ImaginAb. Further information is available at www.oxfordbiomedica.co.uk  and www.oxbsolutions.co.uk .

 

END

 

 

TVRBBGDSUDGBGUB